Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Equity Average: 2020-2024

Historic Equity Average for Silence Therapeutics (SLN) over the last 5 years, with Dec 2024 value amounting to $78.0 million.

  • Silence Therapeutics' Equity Average was N/A to $84.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.1 million, marking a year-over-year change of. This contributed to the annual value of $78.0 million for FY2024, which is 217.02% up from last year.
  • As of FY2024, Silence Therapeutics' Equity Average stood at $78.0 million, which was up 217.02% from $24.6 million recorded in FY2023.
  • Silence Therapeutics' 5-year Equity Average high stood at $78.0 million for FY2024, and its period low was $11.7 million during FY2021.
  • In the last 3 years, Silence Therapeutics' Equity Average had a median value of $24.6 million in 2023 and averaged $40.7 million.
  • In the last 5 years, Silence Therapeutics' Equity Average plummeted by 39.05% in 2021 and then soared by 217.02% in 2024.
  • Silence Therapeutics' Equity Average (MRY) stood at $19.2 million in 2020, then tumbled by 39.05% to $11.7 million in 2021, then soared by 66.72% to $19.5 million in 2022, then grew by 26.35% to $24.6 million in 2023, then soared by 217.02% to $78.0 million in 2024.
  • Its Equity Average was $78.0 million in FY2024, compared to $24.6 million in FY2023 and $19.5 million in FY2022.